🇺🇸 FDA
Pipeline program

TEV-50717

TV50717-CNS-30047

Phase 3 small_molecule terminated

Quick answer

TEV-50717 for Tourette Syndrome is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 3 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Tourette Syndrome
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials